Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. (PFE) is running a Phase 1 study to compare how much of its heart drug tafamidis reaches the blood when given as two new orally disintegrating tablets versus the current capsule under fasting conditions. The goal is to show the new forms match the approved product, which could support easier dosing and help protect a key cardiology franchise.
The trial tests three versions of tafamidis: the current 61 mg free acid capsule, a 61 mg orally disintegrating tablet taken with water, and a 61 mg orally disintegrating tablet taken without water. All aim to deliver the same medicine but with more convenience for patients who may have trouble swallowing standard capsules.
This is an interventional, randomized crossover study in healthy adults, where each participant receives all three tafamidis forms in different sequences separated by washout periods. The trial is open-label with no masking, and its main purpose is to measure drug levels over time rather than to test clinical benefit or safety in patients.
The study was first submitted on May 8, 2026, with the record last updated on May 19, 2026, signaling active management by Pfizer. Primary completion and final completion dates are not yet posted, but investors should expect data within the typical Phase 1 window, which often runs from several months to a bit over a year.
For PFE, a positive bioequivalence readout could support a label expansion to a more flexible tafamidis format, potentially improving adherence and extending product life in a competitive cardiomyopathy market. While near-term revenue impact is modest, the update may be viewed as a steady, low-risk enhancement versus higher-risk cardiology bets from rivals like Alnylam and smaller RNA-based players.
The study remains ongoing with updated details available on the ClinicalTrials.gov portal under identifier NCT07587697.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.